Antitumor efficacy of atorvastatin in lung cancer mice model

Abstract

One of the most prevalent cancers in the world is lung cancer. Various factors, multiple inherited, and acquired mechanisms contribute to  lung carcinogenesis. The cholesterol-lowering medication atorvastatin (ATOR) has been demonstrated to have additional intriguing  biological uses, such as anticancer effects. This study aimed to evaluate the effects of ATOR treatment against lung cancer in mice model.  Forty-five male CD-1 mice were divided into 3 groups (n = 15) as the follows: Group 1 (G1) was used as a normal control. Gps 2 and 3 were  administered with urethane (Ure) (1mg/g) and butylated hydroxytoluene (BHT) (200 mg/kg) for lung cancer initiation and  promotion, respectively. G2 was left as a cancer-bearing group. G3 was post-treated with 10 mg/kg ATOR. The results showed that the  treatment of Ure/BHT-administered mice with ATOR led to a significant decreased in the tumour incidences, multiplicities, and sizes as  compared with each treatment alone. Further, the treatment with ATOR has significantly induced apoptosis in lung tumour cells without  adverse side effects.